Characterizing the burden of uncontrolled acromegaly – a description of real-world patient characteristics in Colombia

Objective: To describe the epidemiology and clinical characteristics, relative to biochemical disease control after treatment initiation, in patients with acromegaly Colombia. Methods: Retrospective chart review of newly diagnosed who initiated medical at referral health institutions Patients controlled vs uncontrolled were analyzed, including comorbidities patterns. In addition, receiving somatostatin analogues (SSAs) as first-line (SSA cohort) compared those other therapy (non-SSA cohort). Results: Data obtained from records 53 showed a mean age 49 years (SD 13.31) female preponderance (33 [62.26%]). After 1 year treatment, 10 (18.9%) SSA cohort achieved complete control, showing significantly lower levels median growth hormone (GH) insulin-like factor-1 (IGF-1) 43 (81.1%) group (p=0.0010 p=0.0001, respectively). During follow-up, acromegaly-related higher non-SSA group. Similarly, percentage physician visits was (n=4/10, 40.0%) (n=31/43, 72.0%) (n=24/38, 63.2%) (n=11/15, 73.3%) cohort. Conclusion: therapy, both GH IGF-1 tended decline over time use SSAs. Lower frequency healthcare resources associated acromegaly. Optimizing adequate patient follow-up drug may improve outcomes promote efficient resources.